Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema

Yoshito Koyanagi, Shigeo Yoshida, Yoshiyuki Kobayashi, Yuki Kubo, Takahito Nakama, Keijiro Ishikawa, Shintaro Nakao, Toshio Hisatomi, Yasuhiro Ikeda, Yuji Oshima, Tatsuro Ishibashi, Koh Hei Sonoda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To examine the relationship between early response to anti-vascular endothelial growth factor (VEGF) treatment and visual prognosis. Methods: We retrospectively separated 20 patients with persistent diabetic macular edema (DME) into two responder status groups based on the reduction of central macular thickness (CMT) from baseline to month 3: a delayed responder group (DRG) (≤25% CMT reduction, n = 11) and an immediate responder group (IRG) (>25% CMT reduction, n = 14). We also separated the patients into two responder status groups based on the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA): a visual nonimprovement group (VNIG) (≥0 logMAR BCVA improvement, n = 11) and a vi sual improvement group (VIG) (<0 logMAR BCVA improvement, n = 14). Finally, we assessed the correlations between logMAR BCVA changes from baseline to month 3 (ΔBCVAM3) and those from baseline to month 12 (ΔBCVAM12). Results: At month 12, BCVA was significantly more improved in the VIG than the VNIG (p < 0.005), but was not significantly different between the DRG and the IRG (p = 0.75). The Pearson correlation coefficient showed a significant relationship between ΔBCVAM3 and ΔBCVAM12 (r = 0.60, p < 0.005). Conclusions: BCVA showed significantly greater improvement in the VIG than in the VNIG. ΔBCVAM3 may predict the visual outcome at month 12 in DME patients treated with anti-VEGF drugs.

Original languageEnglish
Pages (from-to)94-102
Number of pages9
JournalOphthalmologica
Volume239
Issue number2-3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Macular Edema
Vascular Endothelial Growth Factor A
Visual Acuity
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems

Cite this

Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema. / Koyanagi, Yoshito; Yoshida, Shigeo; Kobayashi, Yoshiyuki; Kubo, Yuki; Nakama, Takahito; Ishikawa, Keijiro; Nakao, Shintaro; Hisatomi, Toshio; Ikeda, Yasuhiro; Oshima, Yuji; Ishibashi, Tatsuro; Sonoda, Koh Hei.

In: Ophthalmologica, Vol. 239, No. 2-3, 01.03.2018, p. 94-102.

Research output: Contribution to journalArticle

Koyanagi, Yoshito ; Yoshida, Shigeo ; Kobayashi, Yoshiyuki ; Kubo, Yuki ; Nakama, Takahito ; Ishikawa, Keijiro ; Nakao, Shintaro ; Hisatomi, Toshio ; Ikeda, Yasuhiro ; Oshima, Yuji ; Ishibashi, Tatsuro ; Sonoda, Koh Hei. / Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema. In: Ophthalmologica. 2018 ; Vol. 239, No. 2-3. pp. 94-102.
@article{596bed8d4fd743c69cb3a5e660c183f9,
title = "Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema",
abstract = "Objective: To examine the relationship between early response to anti-vascular endothelial growth factor (VEGF) treatment and visual prognosis. Methods: We retrospectively separated 20 patients with persistent diabetic macular edema (DME) into two responder status groups based on the reduction of central macular thickness (CMT) from baseline to month 3: a delayed responder group (DRG) (≤25{\%} CMT reduction, n = 11) and an immediate responder group (IRG) (>25{\%} CMT reduction, n = 14). We also separated the patients into two responder status groups based on the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA): a visual nonimprovement group (VNIG) (≥0 logMAR BCVA improvement, n = 11) and a vi sual improvement group (VIG) (<0 logMAR BCVA improvement, n = 14). Finally, we assessed the correlations between logMAR BCVA changes from baseline to month 3 (ΔBCVAM3) and those from baseline to month 12 (ΔBCVAM12). Results: At month 12, BCVA was significantly more improved in the VIG than the VNIG (p < 0.005), but was not significantly different between the DRG and the IRG (p = 0.75). The Pearson correlation coefficient showed a significant relationship between ΔBCVAM3 and ΔBCVAM12 (r = 0.60, p < 0.005). Conclusions: BCVA showed significantly greater improvement in the VIG than in the VNIG. ΔBCVAM3 may predict the visual outcome at month 12 in DME patients treated with anti-VEGF drugs.",
author = "Yoshito Koyanagi and Shigeo Yoshida and Yoshiyuki Kobayashi and Yuki Kubo and Takahito Nakama and Keijiro Ishikawa and Shintaro Nakao and Toshio Hisatomi and Yasuhiro Ikeda and Yuji Oshima and Tatsuro Ishibashi and Sonoda, {Koh Hei}",
year = "2018",
month = "3",
day = "1",
doi = "10.1159/000481711",
language = "English",
volume = "239",
pages = "94--102",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "2-3",

}

TY - JOUR

T1 - Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema

AU - Koyanagi, Yoshito

AU - Yoshida, Shigeo

AU - Kobayashi, Yoshiyuki

AU - Kubo, Yuki

AU - Nakama, Takahito

AU - Ishikawa, Keijiro

AU - Nakao, Shintaro

AU - Hisatomi, Toshio

AU - Ikeda, Yasuhiro

AU - Oshima, Yuji

AU - Ishibashi, Tatsuro

AU - Sonoda, Koh Hei

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: To examine the relationship between early response to anti-vascular endothelial growth factor (VEGF) treatment and visual prognosis. Methods: We retrospectively separated 20 patients with persistent diabetic macular edema (DME) into two responder status groups based on the reduction of central macular thickness (CMT) from baseline to month 3: a delayed responder group (DRG) (≤25% CMT reduction, n = 11) and an immediate responder group (IRG) (>25% CMT reduction, n = 14). We also separated the patients into two responder status groups based on the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA): a visual nonimprovement group (VNIG) (≥0 logMAR BCVA improvement, n = 11) and a vi sual improvement group (VIG) (<0 logMAR BCVA improvement, n = 14). Finally, we assessed the correlations between logMAR BCVA changes from baseline to month 3 (ΔBCVAM3) and those from baseline to month 12 (ΔBCVAM12). Results: At month 12, BCVA was significantly more improved in the VIG than the VNIG (p < 0.005), but was not significantly different between the DRG and the IRG (p = 0.75). The Pearson correlation coefficient showed a significant relationship between ΔBCVAM3 and ΔBCVAM12 (r = 0.60, p < 0.005). Conclusions: BCVA showed significantly greater improvement in the VIG than in the VNIG. ΔBCVAM3 may predict the visual outcome at month 12 in DME patients treated with anti-VEGF drugs.

AB - Objective: To examine the relationship between early response to anti-vascular endothelial growth factor (VEGF) treatment and visual prognosis. Methods: We retrospectively separated 20 patients with persistent diabetic macular edema (DME) into two responder status groups based on the reduction of central macular thickness (CMT) from baseline to month 3: a delayed responder group (DRG) (≤25% CMT reduction, n = 11) and an immediate responder group (IRG) (>25% CMT reduction, n = 14). We also separated the patients into two responder status groups based on the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA): a visual nonimprovement group (VNIG) (≥0 logMAR BCVA improvement, n = 11) and a vi sual improvement group (VIG) (<0 logMAR BCVA improvement, n = 14). Finally, we assessed the correlations between logMAR BCVA changes from baseline to month 3 (ΔBCVAM3) and those from baseline to month 12 (ΔBCVAM12). Results: At month 12, BCVA was significantly more improved in the VIG than the VNIG (p < 0.005), but was not significantly different between the DRG and the IRG (p = 0.75). The Pearson correlation coefficient showed a significant relationship between ΔBCVAM3 and ΔBCVAM12 (r = 0.60, p < 0.005). Conclusions: BCVA showed significantly greater improvement in the VIG than in the VNIG. ΔBCVAM3 may predict the visual outcome at month 12 in DME patients treated with anti-VEGF drugs.

UR - http://www.scopus.com/inward/record.url?scp=85040321881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040321881&partnerID=8YFLogxK

U2 - 10.1159/000481711

DO - 10.1159/000481711

M3 - Article

C2 - 29316563

AN - SCOPUS:85040321881

VL - 239

SP - 94

EP - 102

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 2-3

ER -